Source comparison
Tesamorelin + Ipamorelin Blend: Research vs Commercial Peptide Comparison
| Peptide Type | Primary Mechanism | Visceral Fat Reduction | Lean Mass Preservation | Cortisol Impact | Research Dosing | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin (GHRH analog) | GHRH receptor agonism → direct pituitary GH stimulation | 10–15% redu
This comparison does not assign a generated winner or score.
- | Peptide Type | Primary Mechanism | Visceral Fat Reduction | Lean Mass Preservation | Cortisol Impact | Research Dosing | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin (GHRH analog) | GHRH receptor agonism → direct pituitary GH stimulation | 10–15% reduction in 26 weeks (NIH trials) | Indirect via GH-mediated anabolism | No elevation at therapeutic doses | 2mg daily SC before sleep | Gold standard for VAT reduction. Unmatched tissue selectivity || Ipamorelin (GHS) | Ghrelin receptor agonism → pulsatile GH release | Minimal direct effect | Strong. Nitrogen retention + protein synthesis | No elevation (unlike GHRP-2/6) | 200–300mcg 2–3× daily | Best-in-class secretagogue for lean mass during deficit || Tesamorelin + Ipamorelin Blend | Dual-axis GH pathway activation | Combines tesamorelin's VAT selectivity with ipamorelin's GH pulses | Maximised through complementary pathways | No synergistic elevation risk | 2mg tesam + 300mcg ipam daily | Only combination that addresses fat loss
- The comparison underscores why the tesamorelin + ipamorelin blend appears frequently in body recomposition research: it isolates the recomposition-specific benefits of GH elevation (VAT reduction + lean mass retention) without the appetite stimulation, cortisol spikes, or regulatory complexity of exogenous GH or older secretagogues.